A clinical trial for patients with Myelin oligodendrocyte glycoprotein antibody disorder (MogAD)
This is a Global, Multicentre Phase III, Randomised, Double-Blind Clinical Trial. The study currently includes over 120 adults and is actively recruiting adolescents (12-18 years of age) with MOGAD from around the world. In Australia 3 sites are participating in the study, located in NSW.